21906-32-1

Basic information

• Product Name: 3-BROMOPHENYLACETONE
• Synonyms: 3-BROMOPHENYLACETONE;1-(3-BROMOPHENYL)-2-PROPANONE;1-(3-BROMOPHENYL)PROPAN-2-ONE;TIMTEC-BB SBB005833;2-Propanone, 1-(3-bromophenyl)-;3-Bromophenylacetone,99%;1-(3-broMophenyl)-;3-BroMophenylacetone, 99% 5GR
• CAS NO: 21906-32-1
• Molecular Formula: C₉H₉BrO
• Molecular Weight: 213.07
• Product Categories: Aromatic Ketones (substituted)
• Mol File: 21906-32-1.mol

Chemical Properties

• Boiling Point: 247.5°C (rough estimate)
• Flash Point: 75.9 °C
• Appearance: Clear light yellow to dark yellow/Liquid
• Density: 1.3841 (rough estimate)
• Vapor Pressure: 0.00903mmHg at 25°C
• Refractive Index: 1.557-1.56
• CAS DataBase Reference: 3-BROMOPHENYLACETONE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-BROMOPHENYLACETONE(21906-32-1)
• EPA Substance Registry System: 3-BROMOPHENYLACETONE(21906-32-1)

Safety Data

• Hazard Codes: Xn
• Statements: 22-52
• Safety Statements: 24/25
• Hazardous Substances Data: 21906-32-1(Hazardous Substances Data)

Usage

Chemical Properties

clear light yellow liquid

InChI:InChI=1/C9H9BrO/c1-7(11)5-8-3-2-4-9(10)6-8/h2-4,6H,5H2,1H3

Upstream product

• 108-22-5 Isopropenyl acetate 
• 591-19-5 m-Bromoaniline 
• 78191-00-1 N-Methoxy-N-methylacetamide 
• 31938-07-5 (3-bromophenyl)acetonitrile 
• 30118-02-6 2-(3-bromo-phenyl)-acetoacetonitrile 
• 108-86-1 bromobenzene 
• 67-64-1 acetone 
• 98288-51-8 2-(3-bromophenyl)acetyl chloride 
• 506-82-1 dimethylcadmium 
• 108-36-1 1,3-dibromobenzene 
• 1878-67-7 3-Bromophenylacetic acid 
• 917-54-4 methyllithium 
• 15804-72-5 1-bromo-3-[2-nitroprop-1-enyl]benzene 

Downstream Products

• 605681-00-3 3-(3-bromophenyl)-4-(5-chloro-2-pyridyl)-2-butanone 
• 3762-39-8 1-(3-bromophenyl)-2-methylpropan-2-ol 
• 917897-71-3 C₁₀H₁₀BrNO 
• 66952-36-1 1-bromo-3-(prop-1-yn-1-yl)benzene 
• 21906-00-3 3-(3-bromophenyl)-2-butanone 
• 53993-67-2 N-ethyl-1-(3-((trifluoromethyl)thio)phenyl)propan-2-amine 
• 605681-02-5 3-(3-bromophenyl)-4-(5-chloro-2-pyridyl)-2-butanol 

Relevant articles and documents

Asymmetric Catalytic Epoxidation of Terminal Enones for the Synthesis of Triazole Antifungal Agents

An enantioselective epoxidation of α-substituted vinyl ketones was realized to construct the key epoxide intermediates for the synthesis of various triazole antifungal agents. The reaction proceeded efficiently in high yields with good enantioselectivities by employing a chiral N,N′-dioxide/ScIII complex as the chiral catalyst and 35% aq. H2O2 as the oxidant. It enabled the facile transformation for optically active isavuconazole, efinaconazole, and other potential antifungal agents.

Pinacolatoboron fluoride (pinBF) is an efficient fluoride transfer agent for diastereoselective synthesis of benzylic fluorides

The incorporation of alkoxy ligands within a range of alkoxyfluoroboranes and dialkoxyfluoroboranes results in fluoroborane reagents with attenuated Lewis acidity and increased ability to donate fluoride ion(s) when compared to boron trifluoride itself. Pinacolatoboron fluoride (pinBF), prepared in situ from BF3·OEt2 and bis(O-trimethylsilyl)pinacol, has been identified as an efficient fluoride donor which allows highly stereoselective SN1-type epoxide ring-opening (with retention of configuration) of a range of trans-β-methyl-substituted aryl epoxides to give the corresponding syn-fluorohydrins. The substrate scope of this transformation is more broad than the analogous protocol using boron trifluoride alone.

β-fluoroamphetamines via the stereoselective synthesis of benzylic fluorides

A range of substituted aryl epoxides undergo efficient ring-opening hydrofluorination upon treatment with 0.33 equiv of BF3-OEt 2 in CH2Cl2 at -20 -°C to give the corresponding syn-fluorohydrins, consistent with a mechanism involving a stereoselective SN1-type epoxide ring-opening process. The benzylic fluoride products of these reactions are valuable templates for further elaboration, as demonstrated by the preparation of a range of aryl-substituted β-fluoroamphetamines.

ARALKYL AMINES AS CANNABINOID RECEPTOR MODULATORS

Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson’s disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, including alcohol and nicotine addiction, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

SUBSTITUTED SULFONAMIDES

The substituted sulfonamides of the invention are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

SUBSTITUTED AMIDES ACTIVE AT THE CANNABINOID-1 RECEPTOR

Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson s disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

SUBSTITUTED ARYL AMIDES

Novel compounds of structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as psychotropic drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson s disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as, the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors

The invention encompasses the novel compound of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases. STR1 The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.

Mass spectrometric investigations on phenylacetic acid derivatives, IV: Loss of ortho-substituents from ionized phenyl-2-propanones upon electron impact

In the gas phase, the phenyl-2-propanone molecules 2a-4a lose upon electron impact chloro-, bromo-, and iodo-radicals specifically at the orthopOsition of the phenyl group giving rise to strong (M-Hal.)+-ions (70/12 eV; 1st and 2nd FFR) of identical structure as confirmed by their MIKE-CAD-spectra. The daughter ions at m/z 133 from o-chlorophenyl-2-propanone (2a) and 2,2-dimethyl-2,3-dihydro[b]furane (11) are structurally similar but not identical (similarity index 99.8). The collisionally activated (2nd FFR) (M-Br.)+-ions from o-bromophenyl-2-propanone (3a) and 1-bromo-1-phenyl-2-propanone (12) produce virtually congruent spectra. The most impOrtant subsequent fragmentation of the (M-Hal-)+-ions from 2a-4a is the loss of CO which incorporates the C-atom of the carbonyl group exclusively (13C labelling). Mechanistic aspects of the fragmentation sequences are discussed (Figs. 5 and 8).

ACETONYLATION AROMATIQUE HOMOLYTIQUE

Treatment of monosubstituted benzene derivatives with acetone and manganese(III) acetate in acetic acid gave rise to products of homolytic aromatic substitution in fairly good yields and high purity except for toluene.Isomer distribution, relative rates and partial rate factors were determeined for toluene, anisole, chlorobenzene, bromobenzene and benzonitrile.A Hammet plot of the logarithm of the partial rate factors for meta and para positions vs. ?-constants gave a slope ρ of -1.74 +/- 0.40 (confidence interval at the level 95percent).When using ?+-constants the slope becomes ρ+ = -1.25 +/- 0.36.The negative velues of ρ and ρ+ indicated that the acetonyl radical has an appreciable electrophilic character.